Index

Note: Page numbers of article titles are in **boldface** type.

A

Ablation, 7–8
  catheter. See *Catheter ablation.*
  safety of, 251–254
  surgical. See *Surgical ablation.*
  three-dimensional imaging guidance
  for, 244–246

Age, 121

Aldosterone antagonists, 134–135

American Heart Association/American College of Cardiology/European Society of Cardiology 2006 guidelines
  on risk factors for stroke, 151–152

Amiodarone, 6, 90, 112, 114, 124

Amiodarone analogs, 128–131

Anesthesia, for electrical cardioversion, 108

Angiotensin-converting enzyme inhibitors, 133–134

Angiotensin receptor blockers, 134

Antiarrhythmic medications, choice of,
  224–226
  for cardioversion, 226
  for maintenance of sinus rhythm, 127
  investigational, 128, 129
  outpatient initiation of, 226
  rhythm control with, 224

Anticoagulation, 93
  before cardioversion, 221–222
  oral, long-term use of, 155
    after radiofrequency ablation, 155–157
  pericardioversion, 103–106
  risk stratification for,
    220–221

Anticoagulation stroke prevention, in patients with atrial fibrillation, 143–159

Anti-inflammatory agents, 135

Aspirin, for prophylaxis against stroke, 147–150

ATI-2001, 131

Atrial and pulmonary vein, autonomic nerves of, structural anatomy of, 58–59

Atrial appendage, left, excision of, 209–210

Atrial-based pacing, or AV synchronous pacing, benefits of, 162–166

Atrial defibrillators, 174

Atrial fibrillation, anticoagulation stroke prevention in patients with, 143–159
  catheter ablation of, 179–201
  drug therapy for, 121–141
  electrical and pharmacologic cardioversion for, 101–120
  genetics of, 41–51
  goals of therapy and management strategies to achieve goals, 217–235
  historical perspective on, 1–15
  new concepts, mechanisms and remodeling, 53–63
  postoperative, 87–99
  role of pacemakers in management of patients with, 161–178
  status of epidemiology of, 17–40
  surgical approaches for, 203–215
  unanswered questions and future directions in, 237–258

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), 122–123, 179, 254

Atrial flutter, 116
  medical therapy versus catheter ablation in, 68–70
  terminology to describe, 66
  type 1, 65
    ablation of, alternative energy sources for, 81
Atrial flutter (continued)
diagnosis and ablation of, 
computerized 3-D mapping in, 77–80
electrocardiogram in diagnosis of, 68
electrophysiologic mapping of, 70–71, 72–73
pathophysiologic mechanisms of, 66–68
radiofrequency catheter ablation of, 65
outcomes and complications of, 75–76, 79
procedure endpoints for, 74–75
typical, diagnosis and management of, 65–85

Atrial pacing, 92
Atrial repolarization delaying agents, 132–133
Atrial sympathetic innervation, heightened, 53
Atrial therapies, 174
Atrioventricular nodal conduction, regulation by pacing, 169
Atrioventricular node ablation, and pacemaker implantation, 169–170
outcomes and limitations of, 182–183
overview of, 181
techniques of, 181–182

Atropine, 111
Autonomic nerves, atrial and pulmonary vein, structural anatomy of, 58–59
distribution of, in heart, 56–57
Autonomic nervous system, 60
AV synchronous pacing, or atrial-based pacing, benefits of, 162–166
AVE0118, 132
AZD7009, 133
Azimilide, 131–132

B
β-adrenergic receptor antagonists, 89
β-Blockers, 123
Balloon ablation catheters, 246–249
Balloon-based high-intensity focused ultrasound ablation, 248
Balloon-based pulmonary vein isolation, 249
Balloon-based radiofrequency ablation, 248
Balloon-based visually guided laser ablation, 248
Balloon cryoablation, 247–248

Ca2+ transient triggering, sympathetic activation and, 57–58
Calcium channel antagonists, 90–91
Calcium channel blockers, 123
Canadian Trial of Atrial Fibrillation (CTAF), 125
Candidate gene studies, 44–46
Cardiac autonomic innervation, 56–57
Cardiac resynchronization therapy, 172–174
Cardiac surgery, incidence of atrial fibrillation, 89
predictors of atrial fibrillation, 88–89
Cardiomyopathy, tachycardia-induced, prevention of, 218–219
Cardiovascular conditions, 26
Cardiovascular Health Study, 21, 25
Cardiovascular risk factors, 23–25
Cardioversion, 6–7, 152–154
antiarrhythmic medications for, 226
anticoagulation before, 221–222
electrical, and pharmacologic, for atrial fibrillation, 101–120
anesthesia for, 108
complications of, 114–115
energy selection for, 109–110
in implanted devices, 110
internal, via intracardiac catheters, 110
outcomes of, 111
pad or paddle positioning and size for, 108
shock delivery for, 109
waveforms for, 106–108
failed, 113–114
immediate recurrence following, 111–113
indications for, 102–103
pharmacologic, 124
general considerations for, 115
in longer duration atrial fibrillation, 116
Genome-wide association studies (GWAS), 48
Goals of therapy, and strategies to achieve goals, in atrial fibrillation, 217–235

H
Hazards, 18
Heart, autonomic nerve distribution in, 56–57
Heart failure, 230
Hemodynamics, 227–228
Heritable condition, 41–42
Historical perspective, on atrial fibrillation, 1–15
History taking, 227
Hypertension, 29

I
Ibutilide, 112–113, 114
Incidence, prevalence, and lifetime risk, 18–19, 20
Inflammation, 27–28
Initial approach, 227
Insulin resistance, 28–29

L
Laboratory tests, 227
Laser ablation, balloon-based visually guided, 248
Lesion sets for ablation, 207–208

M
Magnesium, 91
Magnetic navigation system, remote, 239–242
Magnetic resonance imaging, for ablation guidance, 244–246
Mapping, 4
3-D mapping, computerized, in diagnosis and ablation of type 1 atrial flutter, 81
Maze procedure, 205–207
Metabolic syndrome, 28–29
Mitral valve disease, 2
Mitral valve surgery, 204
Morbidity and mortality, 18, 204

N
Neural modulation, as potential therapeutic strategy, 60–61
Nonparoxysmal atrial fibrillation, catheter ablation of, 249–251

O
Obesity, 28
Omega-3 fatty acids, 135–136
Open-heart surgery, 230
Origin, localization of, 4–5
Outpatient therapy, versus inpatient therapy, 127–128

P
Pacemaker(s), for physiologic pacing, 162–166
implantation of, atrophicventricular node (junction) ablation and, 169–170
in chronic or permanent atrial fibrillation, 167–169
in sinus node dysfunction, 161
role of, in management of patients with atrial fibrillation, 161–178
Pacemaker diagnostics, 166–167
Pacing, atrophicventricular nodal conduction regulation by, 169
Paroxysmal atrial fibrillation, 170–172, 229
animal models of, sympathetic nerve recordings in, 59–60
catheter ablation of, 237–238
Pathogenesis, 87–88
Pathophysiology, 3–4
Pericardioversion anticoagulation, 103–106
Permanent atrial fibrillation, 229
Persistent atrial fibrillation, 170–172, 228–229
Pharmacologic prophylaxis, 89–92
Pharmacologic therapy, in future, 128, 129
Physical examination, 227
Plasma natriuretic peptides, 30
Polymorphisms, 46, 47
Postoperative atrial fibrillation, 87–99, 230
Precipitating factors, 228
Prevalence, 121, 204
Prevention, 34–35
Prognosis, 22–23
Propafenone, 112
Prophylactic therapy, 92–93
Public health burden, 21
Pulmonary vein(s), anatomic and neural substrates in, 55–56
neural anatomy of, implications of, 59
patterns of activation at, 54–55
Pulmonary vein isolation, balloon-based, 249
Pulmonary vein-left atrial junction, patterns
of activation at, 54–55

R
RAAS, 133–135
Radiofrequency ablation, after long-term use of oral anticoagulation, 155–157
balloon-based, 248–249
Radiofrequency catheter ablation, 180–181
of type 1 atrial flutter, 65, 71–74
outcomes and complications of, 75–76, 79
procedure endpoints for, 74–75
Radiofrequency pulmonary vein isolation, 222–223
Rate control, 92, 222
definition of, 223
therapeutic options for, 224
Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE), 122–123
Recurrence, immediate, following cardioversion, 111–113
Remote magnetic navigation system, 239–242
Remote navigation technology, 239–246
Remote robotic navigation system, 242–244
Rhythm control, 92–93, 124, 222
nonpharmacologic, 226
versus rate control, 122–123
with antiarrhythmic medications, 224
Risk category, 221
Risk factors, 17–18, 23
Robotic navigation system, remote, 242–244
Rythmol Atrial Fibrillation Trial (RAFT), 125

S
Secular trends, 19–21
Serotonin antagonists, 133
Shock delivery, for electrical cardioversion, 109
Sinus node dysfunction, pacemakers in, 161
Sinus rhythm, adjuvant therapy for maintenance of, 133–135
maintenance of, 124–127
Sleep apnea, 30–31
Sotalol, 89, 112, 126
Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T), 124–125
Statins, 91, 135
Stature, 29–30
Steroids, 135
Stroke, anticoagulation prevention of, in patients with atrial fibrillation, 143–159
aspirin for prophylaxis against, 147–150
prophylaxis of, 254–255
risk assessment of, 33–34
risk factor for, 31–32
risk of, 151–152
epidemiology of, 143
stratification schemes for, 143–144
warfarin for prophylaxis against, 144–147, 149–150
Stroke Prevention in Atrial Fibrillation trials, 21, 145, 147, 148, 149
Surgery, 8–10
Surgical ablation, challenges in, 210–211
mechanisms and implications for, 204–205
new approaches to, 207–209
rationale for, 204
reporting results of, 210
technology, limitations of, 211
Surgical approaches, for atrial fibrillation, 203–215
Sympathetic activation, and Ca²⁺-transient triggering, 57–58
Symptomatic Atrial Fibrillation
Investigative Research on Dofetilide (SAFIRE-D), 126
Symptoms, control of, 219

T
Tachycardia-bradycardia syndrome, 230
Tachycardia-induced cardiomyopathy, prevention of, 218–219
Tachycardias, stimulation causing, 57, 58
Tedisamil, 132
Therapy, goals of, 217–220
and strategies to achieve goals, in atrial fibrillation, 217–235
medical, versus catheter ablation, in atrial flutter, 68–70
options for, 220–226
prophylactic, 92–93
recommended, 221
strategy for, choice of, 223
Thromboembolism, prevention of, 217–218
risk factors for, 220–221
Thyroid disease, 25–26

U
Ultrasound ablation, balloon-based high-intensity focused, 248

V
Vagal influences, on cardiac electrophysiology, 57
Valsartan Heart Failure Trial, 22
Verapamil, 112–113
Vernakalant, 132
Veterans Affairs Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF-STAT), 125

W
Warfarin, 222, 254
alternatives to, 221
for prophylaxis against stroke, 144–147, 149–150
Watchman device, 254–255
Wolff-Parkinson-White syndrome, 230–231